The plasma levels of soluble CD22 are elevated in patients with Alzheimer’s disease, and its level was correlated with brain Ab burden, cerebrospinal fluid (CSF) p-tau levels, and baseline cognitive impairment (50). The gene discussed is MAPT; the disease is Cognitive impairment.